Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1970 Oct;49(10):1872–1879. doi: 10.1172/JCI106406

Isotopic studies of therapeutic anticoagulation with a coagulating enzyme

W R Bell 1,2, E Regoeczi 1,2
PMCID: PMC322677  PMID: 5456799

Abstract

The kinetics of the depletion of plasma fibrinogen were studied in seven patients who received fibrinogen-131I 1 hr before an intravenous injection of the coagulating enzyme (CE) derived from the venom of the pit viper, Agkistrodon rhodostoma. Disappearance of the clottable radioactivity labeled fibrinogen from the circulation conformed to an exponential decay with an average half-life of 0.85 hr. The mean clearance rate for protein-bound radioactivity, composed of fibrinogen and it's split products, was 12% of the intravascular pool per hour. The breakdown products of fibrin produced by CE inhibited polymerization of fibrin in vitro.

Studies in five patients performed between the 3rd and 10th day following the administration of CE revealed that the absolute catabolic rates of fibrinogen were subnormal initially, but gradually increased as the fibrinogen concentration returned to normal.

In rabbits, after the administration of CE, regeneration of the fibrinogen pool was markedly prolonged. This delayed regeneration time was not influenced by an excess of antivenene, but rapid regeneration to pretreatment values of plasma fibrinogen was immediately initiated by stimulating fibrinogen synthesis with subcutaneous turpentine.

Full text

PDF
1872

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelson E. Fibrinogen and fibrin, their roles in health and disease. Normal metabolism. Fed Proc. 1965 Jul-Aug;24(4):810–815. [PubMed] [Google Scholar]
  2. Atencio A. C., Chao P. Y., Chen A. Y., Reeve E. B. Fibrinogen response to corticotropin preparations in rabbits. Am J Physiol. 1969 Apr;216(4):773–780. doi: 10.1152/ajplegacy.1969.216.4.773. [DOI] [PubMed] [Google Scholar]
  3. Atencio A. C., Joiner K., Reeve E. B. Experimental and control systems studies of plasma fibrinogen regulation in rabbits. Am J Physiol. 1969 Apr;216(4):764–772. doi: 10.1152/ajplegacy.1969.216.4.764. [DOI] [PubMed] [Google Scholar]
  4. BACK N., GUTH P. S., MUNSON A. E. On the relationship between plasmin and kinin. Ann N Y Acad Sci. 1963 Feb 4;104:53–68. doi: 10.1111/j.1749-6632.1963.tb17652.x. [DOI] [PubMed] [Google Scholar]
  5. Baker L. R., Rubenberg M. L., Dacie J. V., Brain M. C. Fibrinogen catabolism in microangiopathic haemolytic anaemia. Br J Haematol. 1968 Jun;14(6):617–625. doi: 10.1111/j.1365-2141.1968.tb00368.x. [DOI] [PubMed] [Google Scholar]
  6. Bell W. R., Bolton G., Pitney W. R. The effect of arvin on blood coagulation factors. Br J Haematol. 1968 Dec;15(6):589–602. doi: 10.1111/j.1365-2141.1968.tb01581.x. [DOI] [PubMed] [Google Scholar]
  7. Bell W. R., Pitney W. R., Goodwin J. F. Therapeutic defibrination in the treatment of thrombotic disease. Lancet. 1968 Mar 9;1(7541):490–493. doi: 10.1016/s0140-6736(68)91465-7. [DOI] [PubMed] [Google Scholar]
  8. Esnouf M. P., Tunnah G. W. The isolation and properties of the thrombin-like activity from Ancistrodon rhodostoma venom. Br J Haematol. 1967 Jul;13(4):581–590. doi: 10.1111/j.1365-2141.1967.tb00765.x. [DOI] [PubMed] [Google Scholar]
  9. GLADNER J. A., MURTAUGH P. A., FOLK J. E., LAKI K. Nature of peptides released by thrombin. Ann N Y Acad Sci. 1963 Feb 4;104:47–52. doi: 10.1111/j.1749-6632.1963.tb17651.x. [DOI] [PubMed] [Google Scholar]
  10. Gans H., Lowman J. T. The uptake of fibrin and fibrin-degradation products by the isolated perfused rat liver. Blood. 1967 Apr;29(4):526–539. [PubMed] [Google Scholar]
  11. Gordon A. H., Koj A. Changes in the rates of synthesis of certain plasma proteins following tissue damage due to talc injection. A study using the perfused rat liver. Br J Exp Pathol. 1968 Oct;49(5):436–447. [PMC free article] [PubMed] [Google Scholar]
  12. HABERMANN E. Snake venoms, kallikreins, and kininogen. Ann N Y Acad Sci. 1963 Feb 4;104:130–132. doi: 10.1111/j.1749-6632.1963.tb17658.x. [DOI] [PubMed] [Google Scholar]
  13. HASLAM R. J. ROLE OF ADENOSINE DIPHOSPHATE IN THE AGGREGATION OF HUMAN BLOOD-PLATELETS BY THROMBIN AND BY FATTY ACIDS. Nature. 1964 May 23;202:765–768. doi: 10.1038/202765a0. [DOI] [PubMed] [Google Scholar]
  14. Krajewski T., Blombäck B. The location of tyrosine-O-sulphate in fibrinopeptides. Acta Chem Scand. 1968;22(4):1339–1346. doi: 10.3891/acta.chem.scand.22-1339. [DOI] [PubMed] [Google Scholar]
  15. LAKI K., GLADNER J. A. CHEMISTRY AND PHYSIOLOGY OF THE FIBRINOGEN-FIBRIN TRANSITION. Physiol Rev. 1964 Apr;44:127–160. doi: 10.1152/physrev.1964.44.2.127. [DOI] [PubMed] [Google Scholar]
  16. LEE L., McCLUSKEY R. T. Immunohistochemical demonstration of the reticuloendothelial clearance of circulating fibrin aggregates. J Exp Med. 1962 Nov 1;116:611–618. doi: 10.1084/jem.116.5.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. MARGOLIS J. Hagerman factor and capillary permeability. Aust J Exp Biol Med Sci. 1959 Jun;37:239–244. doi: 10.1038/icb.1959.24. [DOI] [PubMed] [Google Scholar]
  18. MARGOLIS J. The interrelationship of coagulation of plasma and release of peptides. Ann N Y Acad Sci. 1963 Feb 4;104:133–145. doi: 10.1111/j.1749-6632.1963.tb17659.x. [DOI] [PubMed] [Google Scholar]
  19. MATTHEWS C. M. The theory of tracer experiments with 131I-labelled plasma proteins. Phys Med Biol. 1957 Jul;2(1):36–53. doi: 10.1088/0031-9155/2/1/305. [DOI] [PubMed] [Google Scholar]
  20. McFarlane A. S. IN VIVO BEHAVIOR OF I-FIBRINOGEN. J Clin Invest. 1963 Mar;42(3):346–361. doi: 10.1172/JCI104721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. NAHAS L., MACFARLANE R. G., DENSON K. W. A STUDY OF THE COAGULANT ACTION OF EIGHT SNAKE VENOMS. Thromb Diath Haemorrh. 1964 Dec 31;12:355–367. [PubMed] [Google Scholar]
  22. Nordström S., Zetterqvist E. Effects of thrombin infusions upon 131-I-labelled fibrinogen in dogs. Acta Physiol Scand. 1968 Jan-Feb;72(1):85–99. doi: 10.1111/j.1748-1716.1968.tb03830.x. [DOI] [PubMed] [Google Scholar]
  23. REGOECZI E., REGOECZI G. E., MCFARLANE A. S. RELATION BETWEEN RATE OF CATABOLISM, PLASMA CONCENTRATION AND POOL SIZE OF FIBRINOGEN. Pflugers Arch Gesamte Physiol Menschen Tiere. 1964 Mar 12;279:17–25. doi: 10.1007/BF00363316. [DOI] [PubMed] [Google Scholar]
  24. Regoeczi E., Bell W. R. In vivo behaviour of the coagulant enzyme from Agkistrodon rhodostoma venom: studies using 131-I-'arvin'. Br J Haematol. 1969 Jun;16(6):573–587. doi: 10.1111/j.1365-2141.1969.tb00438.x. [DOI] [PubMed] [Google Scholar]
  25. Regoeczi E. Fibrinogen catabolism: kinetics of catabolism following sudden elevation of the pool with exogenous fibrinogen. Clin Sci. 1970 Jan;38(1):111–121. doi: 10.1042/cs0380111. [DOI] [PubMed] [Google Scholar]
  26. Regoeczi E., Gergely J., McFarlane A. S. In vivo effects of Agkistrodon rhodostoma venom: studies with fibrinogen-131I. J Clin Invest. 1966 Jul;45(7):1202–1212. doi: 10.1172/JCI105426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Regoeczi E., Rubenberg M. L., Brain M. C. Intravascular haemolysis and disseminated intravascular coagulation. Lancet. 1967 Mar 18;1(7490):601–602. doi: 10.1016/s0140-6736(67)90446-1. [DOI] [PubMed] [Google Scholar]
  28. Regoeczi E., Walton P. L. Effects of clotting on the label in iodinated fibrinogen in different species. Thromb Diath Haemorrh. 1967 Feb 28;17(1-2):237–246. [PubMed] [Google Scholar]
  29. Sharp A. A., Warren B. A., Paxton A. M., Allington M. J. Anticoagulant therapy with a purified fraction of Malayan pit viper venom. Lancet. 1968 Mar 9;1(7541):493–499. doi: 10.1016/s0140-6736(68)91466-9. [DOI] [PubMed] [Google Scholar]
  30. Takeda Y. Studies of the metabolism and distribution of fibrinogen in healthy men with autologous 125-I-labeled fibrinogen. J Clin Invest. 1966 Jan;45(1):103–111. doi: 10.1172/JCI105314. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES